Biopharma co’s fundraising from VCs: a key point you’ll want to address in your pitch is the history of each of your targets. What is the level of validation (particularly genetic) for each of the clinical settings you’re pursuing? Who has tried to drug this target in the...1/5
...past and with what different modalities? Were they successful and if not, why? Did they get into the clinic and if so, what did they show? How challenging is it to get selectivity? Sometimes a target that’s hard to drug can indicate that you will have a competitive...2/5
...moat once you crack the code. On the other hand, if others have shown promising results in the clinic that can also work to your advantage by validating the target further, IF there's some real point of differentiation for your program. VCs will also want to understand...3/5
...where your molecules originated; how much you have evolved them over time; and whether you’ve completed a search to confirm that you have freedom-to-operate in your chemical space. Your pitch should convince investors both that the target is important in a disease...4/5
...with unmet need, and that you have the most promising molecules for that target (or a platform that will get you those molecules). 5/5
@SaraNayeem Very helpful. Thank you.
@SaraNayeem @tresselapp save thread